Last edition
News about "Phase 3 VALOR"
Pfizer and Valneva's Lyme Disease Vaccine Candidate Moves to EMA Review
Pfizer and Valneva’s investigational Lyme disease vaccine PF-07307405 has received EMA validation for its Marketing Authorization Application, triggering the European regulatory review.
Phase 3 VALOR | 17/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members